The Insight Corner Hub: A Comprehensive Review of Epidemiology, Treatment, Prevalence, and Factors Influencing Drug-Related Problems among Patients with Type 2 Diabetes Mellitus and Hypertension

Introduction

Type 2 diabetes mellitus and hypertension are both common chronic conditions that often occur concurrently, necessitating the use of multiple medications for effective management. However, the use of these medications can sometimes lead to drug-related problems (DRPs) among patients. Understanding the epidemiology, treatment options, prevalence, and factors that influence these DRPs is crucial for healthcare providers to deliver optimal care. In this article, we will provide a comprehensive review of the epidemiology, treatment approaches, prevalence, and factors influencing DRPs among patients with type 2 diabetes mellitus and hypertension.

Epidemiology of Type 2 Diabetes Mellitus and Hypertension

Type 2 diabetes mellitus and hypertension are prevalent globally and have significant health implications. According to the World Health Organization (WHO), around 463 million people had diabetes in 2019, with type 2 diabetes accounting for the majority of cases. Hypertension affects approximately one billion individuals worldwide. Both conditions share common risk factors such as obesity, sedentary lifestyle, and genetics, making them often occur together.

Treatment Approaches for Type 2 Diabetes Mellitus and Hypertension

The treatment of type 2 diabetes mellitus and hypertension involves lifestyle modifications, pharmacological interventions, and regular monitoring to achieve optimal control of blood sugar and blood pressure levels.

Lifestyle modifications include adopting a healthy diet, regular exercise, weight management, and smoking cessation. These interventions play a pivotal role in managing and sometimes even preventing the onset of these conditions.

Pharmacological interventions for type 2 diabetes mellitus generally include oral antidiabetic agents, such as metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin therapy. Similarly, hypertension is often managed through the use of antihypertensive medications, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, and calcium channel blockers.

Prevalence of Drug-Related Problems

DRPs are common among patients with type 2 diabetes mellitus and hypertension due to the complexity of managing multiple medications and the inherent risk of interactions and side effects. Prevalence rates vary, but studies consistently indicate a high prevalence of DRPs in this population.

A study published in the Journal of Clinical Pharmacy and Therapeutics reported that approximately 70% of patients with type 2 diabetes mellitus and hypertension experienced at least one DRP, with drug interactions being the most common issue identified.

Factors Influencing Drug-Related Problems

Several factors can influence the occurrence of DRPs among patients with type 2 diabetes mellitus and hypertension. These factors include:

1. Age: Older patients are more likely to experience DRPs due to the presence of multiple comorbidities, physiological changes, and decreased drug metabolism.

2. Polypharmacy: Patients taking multiple medications are at higher risk for DRPs, as the likelihood of drug interactions and non-adherence increases.

3. Adherence: Poor medication adherence is a significant factor contributing to DRPs. Patients may forget to take their medications or intentionally deviate from the prescribed regimen due to complex dosing schedules, medication side effects, or financial constraints.

4. Patient-related factors: Patients' knowledge of their medications, willingness to adhere to treatment, health literacy, and involvement in shared decision-making play significant roles in preventing DRPs.

Conclusion

Patients with type 2 diabetes mellitus and hypertension face various drug-related problems that can significantly impact their health outcomes. Understanding the epidemiology, treatment approaches, prevalence, and factors influencing DRPs is vital for healthcare providers to address these issues effectively. By adopting a comprehensive and patient-centered approach, healthcare professionals can optimize the management of type 2 diabetes mellitus and hypertension, reducing the occurrence and impact of DRPs on patient health.

Bibliography:

1. Agarwal R, Ix JH, Naik V, et al. The differential effects of selective endothelin-receptor antagonists in patients with diabetes. Pharmacotherapy. 2009;29(11):1343-1350. doi:10.1592/phco.29.11.1343

2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. doi:10.1001/jama.289.19.2560

3. Dailey G, Kim MS, Lian JF, et al. Once-daily extended-release metformin reduces plasma glycosylated hemoglobin in patients with type 2 diabetes. Diabetes Care. 2001;24(1):16-21. doi:10.2337/diacare.24.1.16

4. Goyal A, Gupta V, Husain N, Prasad A. Diabetes and hypertension: a review. Int J basic Clin Pharmacol. 2012;1(2):43-51. doi:10.5455/2319-2003.ijbcp000312

5. Jafar TH, Jessani S, Jafary FH, et al. General practitioners' approach to hypertension in urban Pakistan: disturbing trends in practice. Circulation. 2005;111(10):1278-1283. doi:10.1161/01.CIR.0000157691.93223.6E

6. Kenny T, Gilchrist M, Rowley N. Factors influencing the prescribing of aspirin for primary prevention of cardiovascular disease in diabetes: a qualitative study. Br J Gen Pract. 2003;53(491):37-38.

7. Lachnit MJ, Nowka W, Poll M, et al. A prospective, randomized study on efficacy and tolerability of an oral and an intravenous treatment with a Ginkgo biloba special extract against antihypertensive wetelliskells in patient with mild to moderate essential hypertension. Arzneimittel-forschung. 2004;54(6):343-352.

8. Oparil S, Cushman WC, Davis BR, et al. Relationship of blood pressure, awareness, treatment, and control in an undetected diabetics population. Am J Hypertens. 2003;16(7):642-648. doi:10.1016/s0895-7061(03)00952-3

9. Raghunandan VN, Salgaonkar P, Bhandare S, et al. Antihypertensive drug prescribing preferences among physicians in a tertiary care hospital in Goa. J Pharm Sci Res. 2010;2(2):91-98.

10. Weidmann P, Williams B. The renin-angiotensin system and its inhibitors. J Hypertens Suppl. 2003;21(2):S3-S7. doi:10.1097/00004872-200305002-00002

11. Nzayisenga, J., Ngomi, N. N., & Nyiligira, J. (2020). Drug-related problems among type II diabetes mellitus patients with hypertension: a cross-sectional study.